Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium

Sydney, Australia — October 08, 2025 (GLOBE NEWSWIRE) — Sapu Nano announced the presentation of its poster, “Sapu-003: Novel Intravenous Deciparticle™ Everolimus Entering Phase 1 Study in Australia” at the 8th Australian Translational Breast Cancer Research Symposium (ATBCR 2025). Sapu Nano is part of the Sapu family of companies, formed through GMP Biotechnology Limited, a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Oversea Capital Limited.

About SAPU-003 (Deciparticle™ Everolimus)

SAPU-003 leverages Sapu Nano’s proprietary Deciparticle™ technology to deliver everolimus intravenously at sub-20 nm size. The program is entering First-in-Human evaluation in Australia under the HREC/CTN pathway and is designed to improve tumor penetration and systemic exposure compared to oral mTOR inhibitors.

About the Symposium

The Australian Translational Breast Cancer Research Symposium brings together oncology researchers, clinicians, and translational scientists to discuss innovations in breast cancer drug delivery, biomarker science, and clinical program design. The inclusion of Sapu-003 highlights growing interest in sub-20 nm nanomedicine across international oncology forums.

About Sapu Nano

Sapu Nano is an advanced nanomedicine company developing sub-20 nm Deciparticle™ therapeutics for oncology and rare pediatric diseases. The company advances precision formulations created through a joint venture between Oncotelic Therapeutics and Dragon Oversea Capital.